Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ezetimibe

ezetimibe

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ezetimibe

58 trials tracked of ezetimibe: 42 in phase 3 or 4 and 12 with published results. The most-cited published study has 524 citations.

58Trials tracked
42Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 12 Phase 3 30 Phase 2 8 Phase 1 1 Other / NA 7
  1. Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 Completed · 524 cited
  2. Phase 3 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) Completed · 424 cited
  3. Phase 3 A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy Completed · 359 cited
  4. Phase 4 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) Completed · 126 cited
  5. Phase 4 Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Completed · 89 cited
  6. Phase 3 Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Completed · 50 cited
Show 44 more trials
  1. Phase 3 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Completed · 37 cited
  2. Phase 3 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia Completed · 36 cited
  3. Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4 Completed · 29 cited
  4. Phase 3 Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. Completed · 25 cited
  5. Phase 3 A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) Completed · 14 cited
  6. Phase 3 Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE) Completed · 3 cited
  7. Phase 4 Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects Completed
  8. Phase 4 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. Completed
  9. Phase 4 Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED) Completed
  10. Phase 4 Effects of Ezetimibe on the Absorption of Oxidized Cholesterol Completed
  11. Phase 4 A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction Completed
  12. Phase 4 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) Completed
  13. Phase 4 Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study Completed
  14. Phase 4 Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons Completed
  15. Phase 4 A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541) Completed
  16. Phase 4 Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED) Completed
  17. Phase 3 Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study Completed
  18. Phase 3 A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED) Completed
  19. Phase 3 A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833) Completed
  20. Phase 3 Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456) Completed
  21. Phase 3 Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457) Completed
  22. Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 Completed
  23. Phase 3 Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood Completed
  24. Phase 3 Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 Completed
  25. Phase 3 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II) Completed
  26. Phase 3 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe Completed
  27. Phase 3 A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1) Completed
  28. Phase 3 Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522) Completed
  29. Phase 3 LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 Completed
  30. Phase 3 Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study Completed
  31. Phase 3 Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II) Completed
  32. Phase 3 Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I) Completed
  33. Phase 3 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia Completed
  34. Phase 3 A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1) Completed
  35. Phase 3 Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) Completed
  36. Phase 3 To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090) Completed
  37. Phase 2 Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects Completed
  38. Phase 2 An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Completed
  39. Phase 2 Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels Completed
  40. Phase 2 Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis Completed
  41. Phase 2 Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents Completed
  42. Phase 2 A Study of LY3015014 in Participants With High Cholesterol Completed
  43. Phase 2 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects Completed
  44. Phase 2 The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia Completed

Showing the 50 most-cited and recently-updated of 58 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
ABCG2 c.421A allele carriage may correlate with liver enzyme elevations during statin-ezetimibe therapy
Drug Pipeline Sys. Review
ABCG2 c.421A allele carriage may correlate with liver enzyme elevations during statin-ezetimibe therapy Genetic Factors May Influence Liver Risks for Statin Patients
This narrative review analyzes a case series of 11 patients with the ABCG2 c.421A allele experiencing liver enzyme elevations during statin-…
A small case series suggests that a specific genetic variation may link to liver enzyme issues for patients taking a common combination of c…
Frontiers Oct 12, 2026
PCSK9 inhibitors significantly reduce LDL-C levels in patients with atherosclerotic cardiovascular disease
Cardiology Meta-analysis
PCSK9 inhibitors significantly reduce LDL-C levels in patients with atherosclerotic cardiovascular disease PCSK9 inhibitors lower LDL but not stroke risk
This meta-analysis of 63,328 patients evaluated the efficacy and cost-effectiveness of alirocumab, evolocumab, and inclisiran compared to st…
A large meta-analysis finds PCSK9 inhibitors cut LDL and heart attacks, but stroke risk was unchanged. Evolocumab may offer the best value.
Frontiers Aug 9, 2026
PCSK9 inhibitors reduce LDL-C by 35.44% in children with heterozygous familial hypercholesterolaemia
Cardiology Sys. Review
PCSK9 inhibitors reduce LDL-C by 35.44% in children with heterozygous familial hypercholesterolaemia PCSK9 inhibitors lower LDL cholesterol in children with high risk
This systematic review and meta-analysis of randomized controlled trials found that PCSK9 inhibitors as add-on therapy significantly reduced…
New data shows PCSK9 inhibitors significantly lower bad cholesterol in children who do not reach health goals on standard medications.
medRxiv Aug 9, 2026
Guideline on cost-effectiveness of add-on ezetimibe for statin-intolerant acute coronary syndrome patients in Thailand
Drug Pipeline Guideline
Guideline on cost-effectiveness of add-on ezetimibe for statin-intolerant acute coronary syndrome patients in Thailand Add-on ezetimibe may be cost-effective for statin-intolerant patients in Thailand
This cost-utility analysis evaluates add-on ezetimibe versus moderate-intensity statin alone for acute coronary syndrome patients in Thailan…
Adding ezetimibe to moderate-intensity statin therapy appears cost-effective for patients in Thailand who cannot tolerate high-intensity sta…
Frontiers May 20, 2026
Phase 3 trial of oral PCSK9 inhibitor enlicitide in hypercholesterolemia reports no results
Diabetes & Endocrinology Phase III
Phase 3 trial of oral PCSK9 inhibitor enlicitide in hypercholesterolemia reports no results Can a new pill lower cholesterol as well as existing drugs?
A completed phase 3 randomized controlled trial in 301 adults with hypercholesterolemia compared oral PCSK9 inhibitor enlicitide to ezetimib…
A new cholesterol pill called enlicitide finished its final trial, but the results showing how well it lowers bad cholesterol and its safety…
CT.gov Apr 3, 2026